Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03825510 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
A Phase 2 study, sponsored by Crozer-Keystone Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03825510: Completed Phase 2 study, sponsored by Crozer-Keystone Health System.
NCT03825510 is a Phase 2 study that has completed, run by Crozer-Keystone Health System. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03825510, a Phase 2 study, has completed, sponsored by Crozer-Keystone Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine efficacy, safety of Stereotactic Body Radiotherapy (SBRT) in combination with immunotherapy in participants with metastatic non-small cell lung cancer (NSCLC) who are eligible for an immunotherapy agent.
Primary Outcome
Determine overall survival in patients receiving SBRT and immunotherapy as compared to landmark trials of patients receiving immunotherapy alone (Checkmate 057, Keynote 024)
Interventions
- RADIATION Stereotactic Body Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-28 |
| Est. Completion | 2022-03-08 |
| Phase | Phase 2 |
What the finished NCT03825510 record still lists
NCT03825510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Body Radiotherapy is the first listed.
NCT03825510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03825510 about?
NCT03825510 is a clinical study titled "Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect". The purpose of this study is to determine efficacy, safety of Stereotactic Body Radiotherapy (SBRT) in combination with immunotherapy in participants with metastatic non-small cell lung cancer (NSCLC) who are eligible for an immunotherapy agent.
What is the current status of trial NCT03825510?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-04-28. Estimated completion is 2022-03-08.
What interventions are being tested in trial NCT03825510?
The interventions under investigation include: Stereotactic Body Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03825510?
This trial is sponsored by Crozer-Keystone Health System, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03825510's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI